Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

Treating narrowed or blocked heart arteries has evolved over the past 40 years. This week, the FDA approved the latest step in that evolution — a stent that dissolves away, leaving nothing behind.

When the arteries that supply blood to the heart become narrowed or clogged, the condition is known as Coronary Artery Disease (CAD). It makes it difficult for the blood to flow to the heart muscle.

The FDA approved a new emergency stent device to treat perforations in the blood vessels of the heart, the agency’s first new treatment option in the indication in 17 years. Deep tears in coronary ...

The delivery of coronary artery stents is a procedure that affects over 1 million patients each year in the United States. With an aging population, the declining cost of stents and reimbursement ...

Add Yahoo as a preferred source to see more of our stories on Google. Elixir Medical's DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial.

For patients with symptomatic coronary artery disease, the best course of action often involves implanting a drug-eluting stent into the artery where a plaque buildup is blocking blood flow to the ...

A major international study has found that drug-eluting stents, a less-invasive alternative to bypass surgery, are as effective as surgery for many patients with a blockage in the left main coronary ...

Dr. Schneider discusses best practices for dedicated iliac branch devices, factors influencing decisions regarding available ...

Mar. 23 -- FRIDAY, March 23 (HealthDay News) -- Minimally invasive heart bypass surgery results in longer and better quality of life than the use of artery-opening stents for patients who have a ...

The role of endovascular therapy in patients with renal artery stenosis continues to be very controversial. Two reports have added notable findings to the growing body of evidence on this subject. The ...

Elixir Medical’s coronary implant, DynamX bioadaptor, has been proven to significantly reduce the risk of device-related cardiac events compared with current-generation drug-eluting stents in a ...